Company Overview: Bioline RX Ltd.

Industry News

7 Sep

BioLineRx to Present at the 19th Annual Rodman & Renshaw Global Investment Conference in New York

TEL AVIV, Israel, September 7, 2017 /PRNewswire/ — BioLineRx Ltd. (BLRX)(BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that its Chief Executive Officer, Philip Serlin, and its Chief Business Officer, David Malek, will present a company update at the 19th Annual Rodman & Renshaw Global Investment Conference at the...

Read more

8 Aug

Investor Network: Bioline RX Ltd Sponsored ADR to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / August 8, 2017 / Bioline RX Ltd Sponsored ADR (NASDAQ: BLRX) will be discussing their earnings results in their Q2 Earnings Call to be held on Tuesday, August 8, 2017 at 10:00 AM Eastern Time. To listen to the event live – visit https://www.investornetwork.com/company/23623. Replay Information The replay...

Read more

8 Aug

BioLineRx Reports Second Quarter 2017 Financial Results

TEL AVIV, Israel, Aug. 8, 2017 /PRNewswire/ — BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for the second quarter ended June 30, 2017. Highlights and achievements during the second quarter 2017 and to date: Continued execution on multiple clinical development programs for the...

Read more

2 Aug

BioLineRx to Report Second Quarter 2017 Results on August 8, 2017

Management to hold conference call at 10:00 a.m. EDT TEL AVIV, Israel, August 2, 2017 /PRNewswire/ — BioLineRx Ltd. (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it will release its unaudited financial results for the quarter ended June 30, 2017 on Tuesday, August 8, 2017, before...

Read more

26 Jul

BioLineRx Announces Additional Investment From BVF Partners L.P.

TEL AVIV, Israel, July 26, 2017 /PRNewswire/ — BioLineRx Ltd. (BLRX) (BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, today announced that BVF Partners L.P. (BVF), its largest shareholder, has entered into a definitive agreement to make an additional, direct investment of $9.6 million in BioLineRx, increasing its economic interest in...

Read more

10 Jul

BioLineRx Announces Initiation of Phase 1b/2 Trial of BL-8040 in Pancreatic Cancer Under Immunotherapy Collaboration

Combination trial of BL-8040 and atezolizumab are part of initiative for the development of novel cancer immunotherapy combinations TEL AVIV, Israel, July 10, 2017 /PRNewswire/ — BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that Genentech, a member of the Roche Group, has commenced...

Read more

1 Jun

BioLineRx Reports Regulatory Submissions of Three Phase 1b Trials for BL-8040 in Combination With Atezolizumab for Solid Tumors

BioLineRx Ltd. (NASDAQ: BLRX, TASE:BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that Genentech, a member of the Roche Group, has filed a total of three regulatory submissions required to commence Phase 1b trials for BL-8040 in combination with atezolizumab (Tecentriq®), Genentech’s anti-PDL1 cancer immunotherapy,...

Read more

25 May

BioLineRx Reports First Quarter 2017 Financial Results

TEL AVIV, Israel, May 25, 2017 /PRNewswire/ — BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for the first quarter ended March 31, 2017. Highlights and achievements during the first quarter 2017 and to date: Continued advancing the Company’s lead...

Read more

16 May

BioLineRx to Report First Quarter 2017 Results on May 25, 2017

TEL AVIV, Israel, May 16, 2017 /PRNewswire/ — BioLineRx Ltd. (NASDAQ, TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that it will release its unaudited financial results for the quarter ended March 31, 2017 on Thursday, May 25, 2017, before the US markets open. The Company will...

Read more

Page 1 of 812345...Last »

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address